HealthCare Journey for Multiple Sclerosis
  • Home
  • About Us
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey

Welcome to the Virtual MS Center!

Ask any question you want about Multiple Sclerosis and one of our experts will answer it as soon as possible.
CLICK HERE TO ASK YOUR QUESTION!

Questions about Rituxan and Multiple Sclerosis 

5/19/2014

 
Here is My Question:
Is there an increased risk of relapse after stopping Rituxan the way there is with Tysabri? Second, does Rituxan preclude patients from taking other drugs such as Tecfidera or even Tysabri and others in the future? Third, does the JCV+ antibody test done with Tysabri also mean a person has that same risk of PML with Rituxan?

Answer:
These are all very good questions for which we currently have only partial answers.

  • Is there an increased risk of relapse after stopping rituximab?  Current evidence suggests that the return of disease activity after treatment with rituximab does not predictably follow the return of CD20 positive B cells to the circulation. In other words the return of MS disease activity is not predictably linked to the loss of the main biological marker of Rituximab treatment. In contrast the return of disease activity following cessation of treatment with Tysabri is more predictably linked to the loss of the biological effects of Tysabri treatment. Furthermore, the main phase II study of Rituximab treatment in relapsing MS did not report any rebound in MS activity as the effects of rituximab wore off during the follow-up phase. In fact the benefits persisted up to a year after the two Rituxmab treatments were administered at study onset.

  • Does rituximab preclude MS patients from taking other MS drugs in the future?  We have no evidence that rituximab treatment precludes patients from receiving other treatments in the future. However, Rituximab in combination with other immunosuppressive treatments may led to an increased risk of infections including rare infections like PML. This has certainly been the case when rituximab has been used in combination with immunosuppressants and chemotherapies to treat other conditions. Only time and further studies will tell if Rituximab used in combination with other MS treatments increases the risk of these rare complications.

  • Does the JCV antibody test done with tysabri also mean that a person has the same risk of PML with other treatments like Rituximab?  The answer is no. The JCV antibody test assesses the risk of PML on Tysabri treatment only. The risk of PML with other treatments, including Rituximab is very small (estimated at < 1 in 10,000 ). Since more than 50% of patients are JCV antibody positive, it is hard to imagine how the results of this test could have a meaningful impact on PML risk with Rituximab treatment. In contrast the risk of PML in the entire Tysabri population is at least 10 fold higher (1 in 1,000) than with rituximab treatment.

All of these answers must be tempered with some degree of caution as there here have been limited controlled studies of rituximab treatment in MS patients . For the time being these are the best answers that I can provide based on the evidence available.

Rip Kinkel, MD
Leena
5/19/2014 10:40:51 am

Have rebounds been observed in patients who switched from Tysabri to Rituximab?

Eric Olson
5/20/2014 02:26:58 am

Hi Rip (Dr. Kinkle )
Tracy started Retuxan today. She also told me about this site.
I'll keep you abreast of her situation. ... not that you couldn't find out if you wanted to anyway. It's nice to see you're keeping busy and productive. We're looking to build a ranch in Berkeley. We hope all is well.
Thanks
Eric
( your favorite Viking )

Tracy McCann Olson
5/20/2014 09:52:43 am

Hi dr k,

I started rituximab today. We miss you but dr Sloane is great too. So how long before I would know if the circulatory B cells have been reduced and by how much? Also I told the. Ruses in the infusion clinic about the site today. They really liked it. Hope life is good !
Tracy

Yes, Eric is still crazy :)

PG
5/20/2014 03:00:57 pm

Thank you Dr. Kinkel.


Comments are closed.

    RSS Feed

    PLEASE NOTE: This information/opinions on this site should be used as an information source only.  This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment.  Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.
    Read About Our Virtual MS Center Authors

    Archives

    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    July 2013
    June 2013

    Categories

    All
    Accessible Housing And Environmental Modifications
    Anxiety
    Balance
    Bowel Problems
    Caregivers
    Cognitive Function
    Compliance
    David Rintell Ed. D.
    Deborah Backus Blogs
    Depression
    Diagnosis
    Diet
    Dizziness
    Dosing
    Dr. Greenberg's Q&A
    Dr. Kinkel's Q&A
    Dr. Miravalle's Q&A
    Dr. Nielsen's Q&A
    Dr. Osborne's Q&A
    Exercise
    Experimental Treatments
    Eye Surgery
    Fatigue
    Fatique
    Flu Shot
    Foot Drop
    Herbs
    Immunosuppression
    JCV
    Lasik Surgery
    Lesions
    Lori Kostich's Q&A
    Lyme Disease
    Medications
    Migraines
    Mobility
    MRI
    MS Hug
    Other Diseases
    Pain
    PML
    PPMS
    Pregnancy
    Relapse
    Safety
    Sarah Wargo's Q&A
    Sexual Dysfunction
    Side Effects
    Smoking
    Spasticity
    Stem Cell Transplantation
    Steroids
    Stress
    Supplements
    Surgery
    Symptoms
    Treatment
    Urination
    Viruses
    Vision
    Vitamin D
    Vitamins
    Weakness


© 2020 HealthCare Journey, LLC. All Rights Reserved.
HealthCare Journey™ is a trademark of HealthCare Journey, LLC
Picture
  • Home
  • About Us
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey